Noting rising international demand for cell tradition media, Thermo Fisher Scientific introduced at present it’s increasing the dry powder media manufacturing facility.
The Grand Island growth is a part of a $650m multi-year funding from Thermo Fisher, which seeks to spice up the corporate’s whole manufacturing capability in North America, Europe and Asia with versatile, scalable and dependable bioprocessing amenities.
AOF manufacturing area
The Grand Island growth provides greater than 45,000 sq. toes of Animal Origin Free (AOF) manufacturing area. This consists of amenities for the manufacture of Thermo Fisher’s Superior Granulation Expertise (AGT) format and different AOF Dry Powder Media (DPM) merchandise.
The extra capability will assist speed up the growth and manufacturing of biotherapeutics and vaccines by biopharmaceutical producers, biotechnology builders and CDMOs working with biologics, biosimilars, cell therapies and viral vectors.
Thermo Fisher already employs greater than 1,600 folks on the web site: and the growth will add round 100 extra staff members throughout R&D, operations, manufacturing, HR, engineering and upkeep roles. The corporate employs greater than 3,000 folks throughout New York.
Dr. Kate Torchilin, president, biologicals and chemical substances at Thermo Fisher Scientific, explains the funding has duplicated the present manufacturing facility, course of capabilities and tools to offer manufacturing redundancy and shorten product manufacturing lead instances for patrons.
“Our expanded Grand Island web site represents a big milestone in our funding to double our whole manufacturing capability by the top of 2023,” she mentioned. “With the harmonized capabilities of our international manufacturing websites that allow us to show equivalency in manufacturing, we’re in a position to assist present demand whereas priming for future development and constantly enhancing our buyer expertise globally.”
A key product manufactured on the web site is Thermo Fisher’s Gibco cell tradition media line, which has been produced at Grand Island for 60 years. Gibco has been used – or is getting used – to develop and manufacture greater than 250 industrial biologics, protecting cell and gene therapies, mAbs, and vaccines.
International capability growth
Thermo Fisher Scientific’s $650m capital funding program, introduced final yr, covers bioprocessing manufacturing throughout 11 manufacturing websites in North America, Europe and Asia.
Capability growth tasks in Grand Island, N.Y., Miami, Fla., and Inchinnan, Scotland are additionally rising manufacturing capability for Gibco cell tradition media, dietary supplements, and course of liquids in addition to the manufacturing of customer-owned proprietary media formulations.
Different tasks embody new single-use expertise manufacturing websites in Nashville and Singapore; in addition to growth tasks in Logan, Utah; Suzhou, China; Bedford, Mass., and Chelmsford, Mass.